ESM1 and chronic kidney disease: We hypothesized that endocan, ET-1, and NT-proBNP may play a role in endothelial dysfunction in IgAN patients because endothelial injury could be a key factor in the progression of CKD [38], and we should use them as new biomarkers for progressive cases.